#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The Mediterranean diet ( MD ) has been recognized as a model of healthy eating because of its contribution to a healthy lifestyle and a better quality of life .
2-1	16-19	The	abstract[2]	new[2]	appos	2-5[0_2]
2-2	20-33	Mediterranean	abstract[2]	new[2]	_	_
2-3	34-38	diet	abstract[2]	new[2]	_	_
2-4	39-40	(	_	_	_	_
2-5	41-43	MD	abstract	giv	coref	3-1[10_0]
2-6	44-45	)	_	_	_	_
2-7	46-49	has	_	_	_	_
2-8	50-54	been	_	_	_	_
2-9	55-65	recognized	_	_	_	_
2-10	66-68	as	_	_	_	_
2-11	69-70	a	_	_	_	_
2-12	71-76	model	_	_	_	_
2-13	77-79	of	_	_	_	_
2-14	80-87	healthy	abstract[4]	new[4]	ana	2-18[0_4]
2-15	88-94	eating	abstract[4]	new[4]	_	_
2-16	95-102	because	_	_	_	_
2-17	103-105	of	_	_	_	_
2-18	106-109	its	abstract|abstract[6]	giv|new[6]	_	_
2-19	110-122	contribution	abstract[6]	new[6]	_	_
2-20	123-125	to	abstract[6]	new[6]	_	_
2-21	126-127	a	abstract[6]|abstract[7]	new[6]|new[7]	coref	4-39[21_7]
2-22	128-135	healthy	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-23	136-145	lifestyle	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-24	146-149	and	abstract[6]	new[6]	_	_
2-25	150-151	a	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-26	152-158	better	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-27	159-166	quality	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-28	167-169	of	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-29	170-174	life	abstract[6]|abstract[8]|abstract	new[6]|new[8]|new	coref	4-14[17_0]
2-30	175-176	.	_	_	_	_

#Text=The MD is much more than a dietary pattern .
3-1	177-180	The	abstract[10]	giv[10]	coref	4-1[14_10]
3-2	181-183	MD	abstract[10]	giv[10]	_	_
3-3	184-186	is	_	_	_	_
3-4	187-191	much	_	_	_	_
3-5	192-196	more	_	_	_	_
3-6	197-201	than	_	_	_	_
3-7	202-203	a	abstract[12]	new[12]	_	_
3-8	204-211	dietary	event|abstract[12]	new|new[12]	coref	5-17
3-9	212-219	pattern	abstract[12]	new[12]	_	_
3-10	220-221	.	_	_	_	_

#Text=The word diet comes from the Greek diaita and means ‘ way of life ’ and the MD holds true to this meaning as MD covers not only what to eat but how to eat and live ( active lifestyle , prioritizing culinary activities , etc. ) .
4-1	222-225	The	abstract[14]	giv[14]	coref	4-17[18_14]
4-2	226-230	word	abstract|abstract[14]	new|giv[14]	_	_
4-3	231-235	diet	abstract[14]	giv[14]	_	_
4-4	236-241	comes	_	_	_	_
4-5	242-246	from	_	_	_	_
4-6	247-250	the	abstract[15]	new[15]	_	_
4-7	251-256	Greek	abstract[15]	new[15]	_	_
4-8	257-263	diaita	abstract[15]	new[15]	_	_
4-9	264-267	and	_	_	_	_
4-10	268-273	means	abstract	new	coref|none	4-22[19_0]|4-10[0_19]
4-11	274-275	‘	abstract[16]	new[16]	_	_
4-12	276-279	way	abstract[16]	new[16]	_	_
4-13	280-282	of	abstract[16]	new[16]	_	_
4-14	283-287	life	abstract[16]|abstract[17]	new[16]|giv[17]	_	_
4-15	288-289	’	abstract[16]|abstract[17]	new[16]|giv[17]	_	_
4-16	290-293	and	abstract[16]	new[16]	_	_
4-17	294-297	the	abstract[16]|abstract[18]	new[16]|giv[18]	coref	4-25[0_18]
4-18	298-300	MD	abstract[16]|abstract[18]	new[16]|giv[18]	_	_
4-19	301-306	holds	_	_	_	_
4-20	307-311	true	_	_	_	_
4-21	312-314	to	_	_	_	_
4-22	315-319	this	abstract[19]	new[19]	_	_
4-23	320-327	meaning	abstract[19]	new[19]	_	_
4-24	328-330	as	_	_	_	_
4-25	331-333	MD	abstract	giv	coref	6-4[31_0]
4-26	334-340	covers	_	_	_	_
4-27	341-344	not	_	_	_	_
4-28	345-349	only	_	_	_	_
4-29	350-354	what	_	_	_	_
4-30	355-357	to	_	_	_	_
4-31	358-361	eat	_	_	_	_
4-32	362-365	but	_	_	_	_
4-33	366-369	how	_	_	_	_
4-34	370-372	to	_	_	_	_
4-35	373-376	eat	_	_	_	_
4-36	377-380	and	_	_	_	_
4-37	381-385	live	_	_	_	_
4-38	386-387	(	_	_	_	_
4-39	388-394	active	abstract[21]	giv[21]	ana	5-2[0_21]
4-40	395-404	lifestyle	abstract[21]	giv[21]	_	_
4-41	405-406	,	_	_	_	_
4-42	407-419	prioritizing	_	_	_	_
4-43	420-428	culinary	abstract[22]	new[22]	_	_
4-44	429-439	activities	abstract[22]	new[22]	_	_
4-45	440-441	,	_	_	_	_
4-46	442-446	etc.	_	_	_	_
4-47	447-448	)	_	_	_	_
4-48	449-450	.	_	_	_	_

#Text=And it should be preserved in the Mediterranean basin where , in the past decades , dietary trends are departing from traditional dietary patterns .
5-1	451-454	And	_	_	_	_
5-2	455-457	it	abstract	giv	_	_
5-3	458-464	should	_	_	_	_
5-4	465-467	be	_	_	_	_
5-5	468-477	preserved	_	_	_	_
5-6	478-480	in	_	_	_	_
5-7	481-484	the	place[24]	new[24]	_	_
5-8	485-498	Mediterranean	place[24]	new[24]	_	_
5-9	499-504	basin	place[24]	new[24]	_	_
5-10	505-510	where	_	_	_	_
5-11	511-512	,	_	_	_	_
5-12	513-515	in	_	_	_	_
5-13	516-519	the	time[25]	new[25]	_	_
5-14	520-524	past	time[25]	new[25]	_	_
5-15	525-532	decades	time[25]	new[25]	_	_
5-16	533-534	,	_	_	_	_
5-17	535-542	dietary	abstract|abstract[27]	giv|new[27]	coref|coref|coref|coref	5-23|8-14[81_27]|5-23|8-14[81_27]
5-18	543-549	trends	abstract[27]	new[27]	_	_
5-19	550-553	are	_	_	_	_
5-20	554-563	departing	_	_	_	_
5-21	564-568	from	_	_	_	_
5-22	569-580	traditional	abstract[29]	new[29]	_	_
5-23	581-588	dietary	abstract|abstract[29]	giv|new[29]	coref	8-14
5-24	589-597	patterns	abstract[29]	new[29]	_	_
5-25	598-599	.	_	_	_	_

#Text=The principles underlying the MD — widely documented elsewhere — can be summarized as follows :
6-1	600-603	The	abstract[30]	new[30]	_	_
6-2	604-614	principles	abstract[30]	new[30]	_	_
6-3	615-625	underlying	_	_	_	_
6-4	626-629	the	abstract[31]	giv[31]	coref	8-1[78_31]
6-5	630-632	MD	abstract[31]	giv[31]	_	_
6-6	633-634	—	_	_	_	_
6-7	635-641	widely	_	_	_	_
6-8	642-652	documented	_	_	_	_
6-9	653-662	elsewhere	_	_	_	_
6-10	663-664	—	_	_	_	_
6-11	665-668	can	_	_	_	_
6-12	669-671	be	_	_	_	_
6-13	672-682	summarized	_	_	_	_
6-14	683-685	as	_	_	_	_
6-15	686-693	follows	_	_	_	_
6-16	694-695	:	_	_	_	_

#Text=high consumption of fruits , vegetables , cereals ( especially whole seeds ) , legumes , and nuts ; relatively high fat consumption ( up to 40 % of total energy intake ) , mainly monounsaturated fatty acids ( MUFAs ) from extra-virgin olive oil , the main fat used for seasoning and cooking ; moderate to high consumption of fish ; moderate dairy product consumption , usually in the form of yogurt and cheese ; low red meat and meat product consumption ; moderate alcohol consumption , mainly in the form of red wine during meals ; low consumption of simple sugars ( pastries , soft drinks , etc. ) ; and high consumption of herbs and spices — an important source of micronutrients , including calcium ( Ca ) — used to flavor dishes .
7-1	696-700	high	abstract[32]	new[32]	coref	7-63[53_32]
7-2	701-712	consumption	abstract[32]	new[32]	_	_
7-3	713-715	of	abstract[32]	new[32]	_	_
7-4	716-722	fruits	abstract[32]|plant	new[32]|new	_	_
7-5	723-724	,	abstract[32]	new[32]	_	_
7-6	725-735	vegetables	abstract[32]|plant	new[32]|new	_	_
7-7	736-737	,	abstract[32]	new[32]	_	_
7-8	738-745	cereals	abstract[32]|plant	new[32]|new	_	_
7-9	746-747	(	abstract[32]	new[32]	_	_
7-10	748-758	especially	abstract[32]	new[32]	_	_
7-11	759-764	whole	abstract[32]	new[32]	_	_
7-12	765-770	seeds	abstract[32]	new[32]	_	_
7-13	771-772	)	abstract[32]	new[32]	_	_
7-14	773-774	,	abstract[32]	new[32]	_	_
7-15	775-782	legumes	abstract[32]|substance	new[32]|new	_	_
7-16	783-784	,	abstract[32]	new[32]	_	_
7-17	785-788	and	abstract[32]	new[32]	_	_
7-18	789-793	nuts	abstract[32]|plant[37]	new[32]|new[37]	_	_
7-19	794-795	;	abstract[32]|plant[37]	new[32]|new[37]	_	_
7-20	796-806	relatively	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	coref	7-58[49_39]
7-21	807-811	high	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-22	812-815	fat	abstract[32]|plant[37]|substance|abstract[39]	new[32]|new[37]|new|new[39]	coref	7-47[47_0]
7-23	816-827	consumption	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-24	828-829	(	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-25	830-832	up	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-26	833-835	to	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-27	836-838	40	abstract[32]|plant[37]|abstract[39]|quantity[40]	new[32]|new[37]|new[39]|new[40]	_	_
7-28	839-840	%	abstract[32]|plant[37]|abstract[39]|quantity[40]	new[32]|new[37]|new[39]|new[40]	_	_
7-29	841-843	of	abstract[32]|plant[37]|abstract[39]|quantity[40]	new[32]|new[37]|new[39]|new[40]	_	_
7-30	844-849	total	abstract[32]|plant[37]|abstract[39]|quantity[40]|abstract[42]	new[32]|new[37]|new[39]|new[40]|new[42]	_	_
7-31	850-856	energy	abstract[32]|plant[37]|abstract[39]|quantity[40]|substance|abstract[42]	new[32]|new[37]|new[39]|new[40]|new|new[42]	_	_
7-32	857-863	intake	abstract[32]|plant[37]|abstract[39]|quantity[40]|abstract[42]	new[32]|new[37]|new[39]|new[40]|new[42]	_	_
7-33	864-865	)	abstract[32]|plant[37]|abstract[39]	new[32]|new[37]|new[39]	_	_
7-34	866-867	,	abstract[32]	new[32]	_	_
7-35	868-874	mainly	abstract[32]|substance[43]	new[32]|new[43]	appos	7-40[0_43]
7-36	875-890	monounsaturated	abstract[32]|substance[43]	new[32]|new[43]	_	_
7-37	891-896	fatty	abstract[32]|substance[43]	new[32]|new[43]	_	_
7-38	897-902	acids	abstract[32]|substance[43]	new[32]|new[43]	_	_
7-39	903-904	(	_	_	_	_
7-40	905-910	MUFAs	substance	giv	_	_
7-41	911-912	)	_	_	_	_
7-42	913-917	from	_	_	_	_
7-43	918-930	extra-virgin	substance[46]	new[46]	_	_
7-44	931-936	olive	object|substance[46]	new|new[46]	_	_
7-45	937-940	oil	substance[46]	new[46]	_	_
7-46	941-942	,	_	_	_	_
7-47	943-946	the	substance[47]	giv[47]	_	_
7-48	947-951	main	substance[47]	giv[47]	_	_
7-49	952-955	fat	substance[47]	giv[47]	_	_
7-50	956-960	used	_	_	_	_
7-51	961-964	for	_	_	_	_
7-52	965-974	seasoning	substance	new	_	_
7-53	975-978	and	_	_	_	_
7-54	979-986	cooking	_	_	_	_
7-55	987-988	;	_	_	_	_
7-56	989-997	moderate	_	_	_	_
7-57	998-1000	to	_	_	_	_
7-58	1001-1005	high	abstract[49]	giv[49]	coref	7-81[60_49]
7-59	1006-1017	consumption	abstract[49]	giv[49]	_	_
7-60	1018-1020	of	abstract[49]	giv[49]	_	_
7-61	1021-1025	fish	abstract[49]|animal	giv[49]|new	_	_
7-62	1026-1027	;	_	_	_	_
7-63	1028-1036	moderate	abstract[53]	giv[53]	_	_
7-64	1037-1042	dairy	substance|abstract[53]	new|giv[53]	_	_
7-65	1043-1050	product	substance|abstract[53]	new|giv[53]	coref	7-82
7-66	1051-1062	consumption	abstract[53]	giv[53]	_	_
7-67	1063-1064	,	abstract[53]	giv[53]	_	_
7-68	1065-1072	usually	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-69	1073-1075	in	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-70	1076-1079	the	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-71	1080-1084	form	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-72	1085-1087	of	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-73	1088-1094	yogurt	abstract[53]|abstract[54]|substance	giv[53]|new[54]|new	_	_
7-74	1095-1098	and	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-75	1099-1105	cheese	abstract[53]|abstract[54]|substance	giv[53]|new[54]|new	_	_
7-76	1106-1107	;	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-77	1108-1111	low	abstract[53]|abstract[54]|substance[57]	giv[53]|new[54]|new[57]	coref	7-81[0_57]
7-78	1112-1115	red	abstract[53]|abstract[54]|substance[57]	giv[53]|new[54]|new[57]	_	_
7-79	1116-1120	meat	abstract[53]|abstract[54]|substance[57]	giv[53]|new[54]|new[57]	_	_
7-80	1121-1124	and	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-81	1125-1129	meat	abstract[53]|abstract[54]|substance|abstract[60]	giv[53]|new[54]|giv|giv[60]	coref|coref	7-85[62_60]|7-85[62_60]
7-82	1130-1137	product	abstract[53]|abstract[54]|abstract|abstract[60]	giv[53]|new[54]|giv|giv[60]	_	_
7-83	1138-1149	consumption	abstract[53]|abstract[54]|abstract[60]	giv[53]|new[54]|giv[60]	_	_
7-84	1150-1151	;	abstract[53]|abstract[54]	giv[53]|new[54]	_	_
7-85	1152-1160	moderate	abstract[53]|abstract[54]|abstract[62]	giv[53]|new[54]|giv[62]	_	_
7-86	1161-1168	alcohol	abstract[53]|abstract[54]|substance|abstract[62]	giv[53]|new[54]|new|giv[62]	_	_
7-87	1169-1180	consumption	abstract[53]|abstract[54]|abstract[62]	giv[53]|new[54]|giv[62]	_	_
7-88	1181-1182	,	abstract[53]|abstract[54]|abstract[62]	giv[53]|new[54]|giv[62]	_	_
7-89	1183-1189	mainly	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-90	1190-1192	in	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-91	1193-1196	the	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-92	1197-1201	form	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-93	1202-1204	of	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-94	1205-1208	red	abstract[53]|abstract[54]|abstract[62]|abstract[63]|substance[64]	giv[53]|new[54]|giv[62]|new[63]|new[64]	_	_
7-95	1209-1213	wine	abstract[53]|abstract[54]|abstract[62]|abstract[63]|substance[64]	giv[53]|new[54]|giv[62]|new[63]|new[64]	_	_
7-96	1214-1220	during	abstract[53]|abstract[54]|abstract[62]|abstract[63]|substance[64]	giv[53]|new[54]|giv[62]|new[63]|new[64]	_	_
7-97	1221-1226	meals	abstract[53]|abstract[54]|abstract[62]|abstract[63]|substance[64]|event	giv[53]|new[54]|giv[62]|new[63]|new[64]|new	_	_
7-98	1227-1228	;	abstract[53]|abstract[54]|abstract[62]|abstract[63]	giv[53]|new[54]|giv[62]|new[63]	_	_
7-99	1229-1232	low	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-100	1233-1244	consumption	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-101	1245-1247	of	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-102	1248-1254	simple	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|substance[67]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[67]	_	_
7-103	1255-1261	sugars	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|substance[67]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[67]	_	_
7-104	1262-1263	(	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-105	1264-1272	pastries	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|substance	giv[53]|new[54]|giv[62]|new[63]|new[66]|new	_	_
7-106	1273-1274	,	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-107	1275-1279	soft	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|substance[69]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[69]	_	_
7-108	1280-1286	drinks	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|substance[69]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[69]	_	_
7-109	1287-1288	,	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-110	1289-1293	etc.	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-111	1294-1295	)	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-112	1296-1297	;	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-113	1298-1301	and	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]	giv[53]|new[54]|giv[62]|new[63]|new[66]	_	_
7-114	1302-1306	high	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]	_	_
7-115	1307-1318	consumption	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]	_	_
7-116	1319-1321	of	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]	_	_
7-117	1322-1327	herbs	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|plant	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new	_	_
7-118	1328-1331	and	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]	_	_
7-119	1332-1338	spices	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|plant	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new	_	_
7-120	1339-1340	—	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]	_	_
7-121	1341-1343	an	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]	_	_
7-122	1344-1353	important	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]	_	_
7-123	1354-1360	source	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]	_	_
7-124	1361-1363	of	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]	_	_
7-125	1364-1378	micronutrients	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]|substance[74]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]|new[74]	_	_
7-126	1379-1380	,	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]|substance[74]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]|new[74]	_	_
7-127	1381-1390	including	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]|substance[74]	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]|new[74]	_	_
7-128	1391-1398	calcium	abstract[53]|abstract[54]|abstract[62]|abstract[63]|abstract[66]|abstract[70]|abstract[73]|substance[74]|substance	giv[53]|new[54]|giv[62]|new[63]|new[66]|new[70]|new[73]|new[74]|new	_	_
7-129	1399-1400	(	_	_	_	_
7-130	1401-1403	Ca	person	new	_	_
7-131	1404-1405	)	_	_	_	_
7-132	1406-1407	—	_	_	_	_
7-133	1408-1412	used	_	_	_	_
7-134	1413-1415	to	_	_	_	_
7-135	1416-1422	flavor	_	_	_	_
7-136	1423-1429	dishes	object	new	_	_
7-137	1430-1431	.	_	_	_	_

#Text=This traditional diet , however , has been affected by the onslaught of dietary trends of recent decades .
8-1	1432-1436	This	abstract[78]	giv[78]	coref	18-1[176_78]
8-2	1437-1448	traditional	abstract[78]	giv[78]	_	_
8-3	1449-1453	diet	abstract[78]	giv[78]	_	_
8-4	1454-1455	,	_	_	_	_
8-5	1456-1463	however	_	_	_	_
8-6	1464-1465	,	_	_	_	_
8-7	1466-1469	has	_	_	_	_
8-8	1470-1474	been	_	_	_	_
8-9	1475-1483	affected	_	_	_	_
8-10	1484-1486	by	_	_	_	_
8-11	1487-1490	the	abstract[79]	new[79]	_	_
8-12	1491-1500	onslaught	abstract[79]	new[79]	_	_
8-13	1501-1503	of	abstract[79]	new[79]	_	_
8-14	1504-1511	dietary	abstract[79]|abstract|abstract[81]	new[79]|giv|giv[81]	coref|coref	25-6|25-6
8-15	1512-1518	trends	abstract[79]|abstract[81]	new[79]|giv[81]	_	_
8-16	1519-1521	of	abstract[79]|abstract[81]	new[79]|giv[81]	_	_
8-17	1522-1528	recent	abstract[79]|abstract[81]|time[82]	new[79]|giv[81]|new[82]	_	_
8-18	1529-1536	decades	abstract[79]|abstract[81]|time[82]	new[79]|giv[81]|new[82]	_	_
8-19	1537-1538	.	_	_	_	_

#Text=Osteoporosis ( OP ) is among the diseases with the highest incidence in advanced age , i. e. , coronary heart diseases , cancer , respiratory system diseases , depression , and neurodegenerative diseases such as Alzheimer ’s disease .
9-1	1539-1551	Osteoporosis	abstract	new	appos	9-3
9-2	1552-1553	(	_	_	_	_
9-3	1554-1556	OP	abstract	giv	coref	9-7[85_0]
9-4	1557-1558	)	_	_	_	_
9-5	1559-1561	is	_	_	_	_
9-6	1562-1567	among	_	_	_	_
9-7	1568-1571	the	abstract[85]	giv[85]	coref	10-3[0_85]
9-8	1572-1580	diseases	abstract[85]	giv[85]	_	_
9-9	1581-1585	with	abstract[85]	giv[85]	_	_
9-10	1586-1589	the	abstract[85]|abstract[86]	giv[85]|new[86]	coref	13-32[136_86]
9-11	1590-1597	highest	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-12	1598-1607	incidence	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-13	1608-1610	in	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-14	1611-1619	advanced	abstract[85]|abstract[86]|abstract[87]	giv[85]|new[86]|new[87]	_	_
9-15	1620-1623	age	abstract[85]|abstract[86]|abstract[87]	giv[85]|new[86]|new[87]	_	_
9-16	1624-1625	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-17	1626-1628	i.	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-18	1629-1631	e.	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-19	1632-1633	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-20	1634-1642	coronary	abstract[85]|abstract[86]|object|abstract[90]	giv[85]|new[86]|new|new[90]	_	_
9-21	1643-1648	heart	abstract[85]|abstract[86]|object|abstract[90]	giv[85]|new[86]|new|new[90]	_	_
9-22	1649-1657	diseases	abstract[85]|abstract[86]|abstract[90]	giv[85]|new[86]|new[90]	_	_
9-23	1658-1659	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-24	1660-1666	cancer	abstract[85]|abstract[86]|abstract	giv[85]|new[86]|new	_	_
9-25	1667-1668	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-26	1669-1680	respiratory	abstract[85]|abstract[86]|abstract[93]	giv[85]|new[86]|new[93]	_	_
9-27	1681-1687	system	abstract[85]|abstract[86]|object|abstract[93]	giv[85]|new[86]|new|new[93]	_	_
9-28	1688-1696	diseases	abstract[85]|abstract[86]|abstract[93]	giv[85]|new[86]|new[93]	_	_
9-29	1697-1698	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-30	1699-1709	depression	abstract[85]|abstract[86]|abstract	giv[85]|new[86]|new	_	_
9-31	1710-1711	,	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-32	1712-1715	and	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
9-33	1716-1733	neurodegenerative	abstract[85]|abstract[86]|abstract[95]	giv[85]|new[86]|new[95]	coref	16-23[170_95]
9-34	1734-1742	diseases	abstract[85]|abstract[86]|abstract[95]	giv[85]|new[86]|new[95]	_	_
9-35	1743-1747	such	abstract[85]|abstract[86]|abstract[95]	giv[85]|new[86]|new[95]	_	_
9-36	1748-1750	as	abstract[85]|abstract[86]|abstract[95]	giv[85]|new[86]|new[95]	_	_
9-37	1751-1760	Alzheimer	abstract[85]|abstract[86]|abstract[95]|abstract[96]	giv[85]|new[86]|new[95]|new[96]	_	_
9-38	1761-1763	’s	abstract[85]|abstract[86]|abstract[95]|abstract[96]	giv[85]|new[86]|new[95]|new[96]	_	_
9-39	1764-1771	disease	abstract[85]|abstract[86]|abstract[95]	giv[85]|new[86]|new[95]	_	_
9-40	1772-1773	.	_	_	_	_

#Text=Associated with OP , especially prevalent among older women , is bone fracture risk .
10-1	1774-1784	Associated	_	_	_	_
10-2	1785-1789	with	_	_	_	_
10-3	1790-1792	OP	abstract	giv	coref	11-11
10-4	1793-1794	,	_	_	_	_
10-5	1795-1805	especially	_	_	_	_
10-6	1806-1815	prevalent	_	_	_	_
10-7	1816-1821	among	_	_	_	_
10-8	1822-1827	older	person[98]	new[98]	coref	14-16[0_98]
10-9	1828-1833	women	person[98]	new[98]	_	_
10-10	1834-1835	,	_	_	_	_
10-11	1836-1838	is	_	_	_	_
10-12	1839-1843	bone	object|abstract[101]	new|new[101]	coref|coref|coref|coref	11-19|12-33[125_101]|11-19|12-33[125_101]
10-13	1844-1852	fracture	abstract|abstract[101]	new|new[101]	coref	14-42[152_0]
10-14	1853-1857	risk	abstract[101]	new[101]	_	_
10-15	1858-1859	.	_	_	_	_

#Text=This growing global health problem suggests that the prevention of OP and its complications and the maintenance of bone mass are public health concerns .
11-1	1860-1864	This	abstract[103]	new[103]	_	_
11-2	1865-1872	growing	abstract[103]	new[103]	_	_
11-3	1873-1879	global	abstract[103]	new[103]	_	_
11-4	1880-1886	health	abstract|abstract[103]	new|new[103]	coref	19-15[184_0]
11-5	1887-1894	problem	abstract[103]	new[103]	_	_
11-6	1895-1903	suggests	_	_	_	_
11-7	1904-1908	that	_	_	_	_
11-8	1909-1912	the	abstract[104]	new[104]	ana	11-13[0_104]
11-9	1913-1923	prevention	abstract[104]	new[104]	_	_
11-10	1924-1926	of	abstract[104]	new[104]	_	_
11-11	1927-1929	OP	abstract[104]|abstract	new[104]|giv	coref	12-1
11-12	1930-1933	and	_	_	_	_
11-13	1934-1937	its	abstract|abstract[107]	giv|new[107]	coref|coref	15-10[158_107]|15-10[158_107]
11-14	1938-1951	complications	abstract[107]	new[107]	_	_
11-15	1952-1955	and	_	_	_	_
11-16	1956-1959	the	abstract[108]	new[108]	coref	11-22[111_108]
11-17	1960-1971	maintenance	abstract[108]	new[108]	_	_
11-18	1972-1974	of	abstract[108]	new[108]	_	_
11-19	1975-1979	bone	abstract[108]|object|quantity[110]	new[108]|giv|new[110]	coref|coref|coref|coref	12-10|12-11[0_110]|12-10|12-11[0_110]
11-20	1980-1984	mass	abstract[108]|quantity[110]	new[108]|new[110]	_	_
11-21	1985-1988	are	_	_	_	_
11-22	1989-1995	public	abstract[111]	giv[111]	_	_
11-23	1996-2002	health	abstract[111]	giv[111]	_	_
11-24	2003-2011	concerns	abstract[111]	giv[111]	_	_
11-25	2012-2013	.	_	_	_	_

#Text=OP is a systemic disease characterized by a low bone mass index and destruction of the microarchitecture of bone mass — i. e. , bone mineral density ( BMD ) — posing a major risk of fractures .
12-1	2014-2016	OP	person	giv	coref	12-3[113_0]
12-2	2017-2019	is	_	_	_	_
12-3	2020-2021	a	abstract[113]	giv[113]	coref	13-20[0_113]
12-4	2022-2030	systemic	abstract[113]	giv[113]	_	_
12-5	2031-2038	disease	abstract[113]	giv[113]	_	_
12-6	2039-2052	characterized	_	_	_	_
12-7	2053-2055	by	_	_	_	_
12-8	2056-2057	a	abstract[116]	new[116]	_	_
12-9	2058-2061	low	abstract[116]	new[116]	_	_
12-10	2062-2066	bone	object|abstract[116]	giv|new[116]	coref	12-19
12-11	2067-2071	mass	quantity|abstract[116]	giv|new[116]	coref	12-19[120_0]
12-12	2072-2077	index	abstract[116]	new[116]	_	_
12-13	2078-2081	and	_	_	_	_
12-14	2082-2093	destruction	event[117]	new[117]	_	_
12-15	2094-2096	of	event[117]	new[117]	_	_
12-16	2097-2100	the	event[117]|abstract[118]	new[117]|new[118]	_	_
12-17	2101-2118	microarchitecture	event[117]|abstract[118]	new[117]|new[118]	_	_
12-18	2119-2121	of	event[117]|abstract[118]	new[117]|new[118]	_	_
12-19	2122-2126	bone	event[117]|abstract[118]|object|abstract[120]	new[117]|new[118]|giv|giv[120]	coref|coref|coref|coref	12-25|13-9[130_120]|12-25|13-9[130_120]
12-20	2127-2131	mass	event[117]|abstract[118]|abstract[120]	new[117]|new[118]|giv[120]	_	_
12-21	2132-2133	—	_	_	_	_
12-22	2134-2136	i.	_	_	_	_
12-23	2137-2139	e.	_	_	_	_
12-24	2140-2141	,	_	_	_	_
12-25	2142-2146	bone	object|abstract[123]	giv|new[123]	appos|coref|appos|coref	12-29[0_123]|13-9|12-29[0_123]|13-9
12-26	2147-2154	mineral	substance|abstract[123]	new|new[123]	_	_
12-27	2155-2162	density	abstract[123]	new[123]	_	_
12-28	2163-2164	(	_	_	_	_
12-29	2165-2168	BMD	abstract	giv	coref	18-17[179_0]
12-30	2169-2170	)	_	_	_	_
12-31	2171-2172	—	_	_	_	_
12-32	2173-2179	posing	_	_	_	_
12-33	2180-2181	a	abstract[125]	giv[125]	coref	16-15[167_125]
12-34	2182-2187	major	abstract[125]	giv[125]	_	_
12-35	2188-2192	risk	abstract[125]	giv[125]	_	_
12-36	2193-2195	of	abstract[125]	giv[125]	_	_
12-37	2196-2205	fractures	abstract[125]|event	giv[125]|new	coref	13-13
12-38	2206-2207	.	_	_	_	_

#Text=There are no symptoms indicating a reduction in bone mass , and fractures are the only clinical consequences of OP ; therefore , despite being the most common bone disease , the incidence is difficult to establish , and the prevalence is often based on estimates using indirect indicators such as fractures .
13-1	2208-2213	There	_	_	_	_
13-2	2214-2217	are	_	_	_	_
13-3	2218-2220	no	abstract[127]	new[127]	_	_
13-4	2221-2229	symptoms	abstract[127]	new[127]	_	_
13-5	2230-2240	indicating	_	_	_	_
13-6	2241-2242	a	abstract[128]	new[128]	coref	16-12[166_128]
13-7	2243-2252	reduction	abstract[128]	new[128]	_	_
13-8	2253-2255	in	abstract[128]	new[128]	_	_
13-9	2256-2260	bone	abstract[128]|object|abstract[130]	new[128]|giv|giv[130]	coref|coref|coref|coref	13-29|15-16[160_130]|13-29|15-16[160_130]
13-10	2261-2265	mass	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
13-11	2266-2267	,	_	_	_	_
13-12	2268-2271	and	_	_	_	_
13-13	2272-2281	fractures	abstract	giv	coref	13-15[132_0]
13-14	2282-2285	are	_	_	_	_
13-15	2286-2289	the	abstract[132]	giv[132]	coref	13-52[0_132]
13-16	2290-2294	only	abstract[132]	giv[132]	_	_
13-17	2295-2303	clinical	abstract[132]	giv[132]	_	_
13-18	2304-2316	consequences	abstract[132]	giv[132]	_	_
13-19	2317-2319	of	abstract[132]	giv[132]	_	_
13-20	2320-2322	OP	abstract[132]|abstract	giv[132]|giv	coref	13-26[135_0]
13-21	2323-2324	;	abstract[132]	giv[132]	_	_
13-22	2325-2334	therefore	abstract[132]	giv[132]	_	_
13-23	2335-2336	,	_	_	_	_
13-24	2337-2344	despite	_	_	_	_
13-25	2345-2350	being	_	_	_	_
13-26	2351-2354	the	abstract[135]	giv[135]	coref	15-7[157_135]
13-27	2355-2359	most	abstract[135]	giv[135]	_	_
13-28	2360-2366	common	abstract[135]	giv[135]	_	_
13-29	2367-2371	bone	object|abstract[135]	giv|giv[135]	coref	14-45
13-30	2372-2379	disease	abstract[135]	giv[135]	_	_
13-31	2380-2381	,	_	_	_	_
13-32	2382-2385	the	abstract[136]	giv[136]	_	_
13-33	2386-2395	incidence	abstract[136]	giv[136]	_	_
13-34	2396-2398	is	_	_	_	_
13-35	2399-2408	difficult	_	_	_	_
13-36	2409-2411	to	_	_	_	_
13-37	2412-2421	establish	_	_	_	_
13-38	2422-2423	,	_	_	_	_
13-39	2424-2427	and	_	_	_	_
13-40	2428-2431	the	abstract[137]	new[137]	coref	14-4[0_137]
13-41	2432-2442	prevalence	abstract[137]	new[137]	_	_
13-42	2443-2445	is	_	_	_	_
13-43	2446-2451	often	_	_	_	_
13-44	2452-2457	based	_	_	_	_
13-45	2458-2460	on	_	_	_	_
13-46	2461-2470	estimates	abstract	new	_	_
13-47	2471-2476	using	_	_	_	_
13-48	2477-2485	indirect	abstract[139]	new[139]	_	_
13-49	2486-2496	indicators	abstract[139]	new[139]	_	_
13-50	2497-2501	such	abstract[139]	new[139]	_	_
13-51	2502-2504	as	abstract[139]	new[139]	_	_
13-52	2505-2514	fractures	abstract[139]|event	new[139]|giv	coref	23-18[212_0]
13-53	2515-2516	.	_	_	_	_

#Text=In Spain , prevalence , as determined by densitometry , is about 30 % in women aged 50 years old , increasing to 50 % in women older than 70 years old . About 40 % of Caucasian women will suffer at least one bone fracture after their 50s .
14-1	2517-2519	In	_	_	_	_
14-2	2520-2525	Spain	place	new	_	_
14-3	2526-2527	,	_	_	_	_
14-4	2528-2538	prevalence	abstract	giv	coref	14-12[144_0]
14-5	2539-2540	,	_	_	_	_
14-6	2541-2543	as	_	_	_	_
14-7	2544-2554	determined	_	_	_	_
14-8	2555-2557	by	_	_	_	_
14-9	2558-2570	densitometry	abstract	new	_	_
14-10	2571-2572	,	_	_	_	_
14-11	2573-2575	is	_	_	_	_
14-12	2576-2581	about	abstract[144]	giv[144]	coref	15-4[156_144]
14-13	2582-2584	30	abstract[144]	giv[144]	_	_
14-14	2585-2586	%	abstract[144]	giv[144]	_	_
14-15	2587-2589	in	abstract[144]	giv[144]	_	_
14-16	2590-2595	women	abstract[144]|person	giv[144]|giv	coref	14-27[148_0]
14-17	2596-2600	aged	_	_	_	_
14-18	2601-2603	50	time[146]	new[146]	_	_
14-19	2604-2609	years	time[146]	new[146]	_	_
14-20	2610-2613	old	_	_	_	_
14-21	2614-2615	,	_	_	_	_
14-22	2616-2626	increasing	_	_	_	_
14-23	2627-2629	to	_	_	_	_
14-24	2630-2632	50	quantity[147]	new[147]	_	_
14-25	2633-2634	%	quantity[147]	new[147]	_	_
14-26	2635-2637	in	quantity[147]	new[147]	_	_
14-27	2638-2643	women	quantity[147]|person[148]	new[147]|giv[148]	ana	14-48[0_148]
14-28	2644-2649	older	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-29	2650-2654	than	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-30	2655-2657	70	quantity[147]|person[148]|time[149]	new[147]|giv[148]|new[149]	_	_
14-31	2658-2663	years	quantity[147]|person[148]|time[149]	new[147]|giv[148]|new[149]	_	_
14-32	2664-2667	old	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-33	2668-2669	.	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-34	2670-2675	About	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-35	2676-2678	40	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-36	2679-2680	%	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-37	2681-2683	of	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-38	2684-2693	Caucasian	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-39	2694-2699	women	quantity[147]|person[148]|quantity[150]	new[147]|giv[148]|new[150]	_	_
14-40	2700-2704	will	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-41	2705-2711	suffer	quantity[147]|person[148]	new[147]|giv[148]	_	_
14-42	2712-2714	at	quantity[147]|person[148]|abstract[152]	new[147]|giv[148]|giv[152]	coref	18-12[0_152]
14-43	2715-2720	least	quantity[147]|person[148]|abstract[152]	new[147]|giv[148]|giv[152]	_	_
14-44	2721-2724	one	quantity[147]|person[148]|abstract[152]	new[147]|giv[148]|giv[152]	_	_
14-45	2725-2729	bone	quantity[147]|person[148]|object|abstract[152]	new[147]|giv[148]|giv|giv[152]	coref	15-16
14-46	2730-2738	fracture	quantity[147]|person[148]|abstract[152]	new[147]|giv[148]|giv[152]	_	_
14-47	2739-2744	after	_	_	_	_
14-48	2745-2750	their	person|time[154]	giv|new[154]	coref|coref	19-18[186_0]|19-18[186_0]
14-49	2751-2754	50s	time[154]	new[154]	_	_
14-50	2755-2756	.	_	_	_	_

#Text=Strategies to minimize the prevalence of the disease and its complications would be to enhance bone mass and reduce loss at advanced ages .
15-1	2757-2767	Strategies	abstract	new	_	_
15-2	2768-2770	to	_	_	_	_
15-3	2771-2779	minimize	_	_	_	_
15-4	2780-2783	the	abstract[156]	giv[156]	_	_
15-5	2784-2794	prevalence	abstract[156]	giv[156]	_	_
15-6	2795-2797	of	abstract[156]	giv[156]	_	_
15-7	2798-2801	the	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
15-8	2802-2809	disease	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
15-9	2810-2813	and	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
15-10	2814-2817	its	abstract[156]|abstract[157]|abstract[158]	giv[156]|giv[157]|giv[158]	_	_
15-11	2818-2831	complications	abstract[156]|abstract[157]|abstract[158]	giv[156]|giv[157]|giv[158]	_	_
15-12	2832-2837	would	_	_	_	_
15-13	2838-2840	be	_	_	_	_
15-14	2841-2843	to	_	_	_	_
15-15	2844-2851	enhance	_	_	_	_
15-16	2852-2856	bone	substance|abstract[160]	giv|giv[160]	coref|coref	19-15|19-15
15-17	2857-2861	mass	abstract[160]	giv[160]	_	_
15-18	2862-2865	and	_	_	_	_
15-19	2866-2872	reduce	_	_	_	_
15-20	2873-2877	loss	abstract	new	_	_
15-21	2878-2880	at	_	_	_	_
15-22	2881-2889	advanced	abstract[162]	new[162]	_	_
15-23	2890-2894	ages	abstract[162]	new[162]	_	_
15-24	2895-2896	.	_	_	_	_

#Text=There is convincing scientific evidence supporting the MD ’s role in the reduction of overall risk for diabetes , cardiovascular , and neurodegenerative diseases .
16-1	2897-2902	There	_	_	_	_
16-2	2903-2905	is	_	_	_	_
16-3	2906-2916	convincing	_	_	_	_
16-4	2917-2927	scientific	abstract[163]	new[163]	coref	17-10[173_163]
16-5	2928-2936	evidence	abstract[163]	new[163]	_	_
16-6	2937-2947	supporting	_	_	_	_
16-7	2948-2951	the	abstract[165]	new[165]	coref	19-8[181_165]
16-8	2952-2954	MD	place[164]|abstract[165]	new[164]|new[165]	_	_
16-9	2955-2957	’s	place[164]|abstract[165]	new[164]|new[165]	_	_
16-10	2958-2962	role	abstract[165]	new[165]	_	_
16-11	2963-2965	in	abstract[165]	new[165]	_	_
16-12	2966-2969	the	abstract[165]|abstract[166]	new[165]|giv[166]	coref	17-20[175_166]
16-13	2970-2979	reduction	abstract[165]|abstract[166]	new[165]|giv[166]	_	_
16-14	2980-2982	of	abstract[165]|abstract[166]	new[165]|giv[166]	_	_
16-15	2983-2990	overall	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-16	2991-2995	risk	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-17	2996-2999	for	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-18	3000-3008	diabetes	abstract[165]|abstract[166]|abstract[167]|abstract	new[165]|giv[166]|giv[167]|new	_	_
16-19	3009-3010	,	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-20	3011-3025	cardiovascular	abstract[165]|abstract[166]|abstract[167]|abstract	new[165]|giv[166]|giv[167]|new	_	_
16-21	3026-3027	,	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-22	3028-3031	and	abstract[165]|abstract[166]|abstract[167]	new[165]|giv[166]|giv[167]	_	_
16-23	3032-3049	neurodegenerative	abstract[165]|abstract[166]|abstract[167]|abstract[170]	new[165]|giv[166]|giv[167]|giv[170]	_	_
16-24	3050-3058	diseases	abstract[165]|abstract[166]|abstract[167]|abstract[170]	new[165]|giv[166]|giv[167]|giv[170]	_	_
16-25	3059-3060	.	_	_	_	_

#Text=Regarding site-specific cancers and inflammatory and metabolic conditions , the evidence is suggestive or weak and is unconvincing regarding low-density lipid reduction .
17-1	3061-3070	Regarding	_	_	_	_
17-2	3071-3084	site-specific	abstract[171]	new[171]	_	_
17-3	3085-3092	cancers	abstract[171]	new[171]	_	_
17-4	3093-3096	and	_	_	_	_
17-5	3097-3109	inflammatory	abstract[172]	new[172]	_	_
17-6	3110-3113	and	abstract[172]	new[172]	_	_
17-7	3114-3123	metabolic	abstract[172]	new[172]	_	_
17-8	3124-3134	conditions	abstract[172]	new[172]	_	_
17-9	3135-3136	,	_	_	_	_
17-10	3137-3140	the	abstract[173]	giv[173]	coref	19-3[180_173]
17-11	3141-3149	evidence	abstract[173]	giv[173]	_	_
17-12	3150-3152	is	_	_	_	_
17-13	3153-3163	suggestive	_	_	_	_
17-14	3164-3166	or	_	_	_	_
17-15	3167-3171	weak	_	_	_	_
17-16	3172-3175	and	_	_	_	_
17-17	3176-3178	is	_	_	_	_
17-18	3179-3191	unconvincing	_	_	_	_
17-19	3192-3201	regarding	_	_	_	_
17-20	3202-3213	low-density	abstract[175]	giv[175]	_	_
17-21	3214-3219	lipid	abstract|abstract[175]	new|giv[175]	_	_
17-22	3220-3229	reduction	abstract[175]	giv[175]	_	_
17-23	3230-3231	.	_	_	_	_

#Text=The MD has been shown to modestly reduce the risk of fracture and is associated with higher BMD .
18-1	3232-3235	The	abstract[176]	giv[176]	coref	19-11[182_176]
18-2	3236-3238	MD	abstract[176]	giv[176]	_	_
18-3	3239-3242	has	_	_	_	_
18-4	3243-3247	been	_	_	_	_
18-5	3248-3253	shown	_	_	_	_
18-6	3254-3256	to	_	_	_	_
18-7	3257-3265	modestly	_	_	_	_
18-8	3266-3272	reduce	_	_	_	_
18-9	3273-3276	the	abstract[177]	new[177]	coref	20-23[193_177]
18-10	3277-3281	risk	abstract[177]	new[177]	_	_
18-11	3282-3284	of	abstract[177]	new[177]	_	_
18-12	3285-3293	fracture	abstract[177]|abstract	new[177]|giv	coref	20-23
18-13	3294-3297	and	_	_	_	_
18-14	3298-3300	is	_	_	_	_
18-15	3301-3311	associated	_	_	_	_
18-16	3312-3316	with	_	_	_	_
18-17	3317-3323	higher	abstract[179]	giv[179]	_	_
18-18	3324-3327	BMD	abstract[179]	giv[179]	_	_
18-19	3328-3329	.	_	_	_	_

#Text=Thus , the overall evidence points toward the role of the MD in maintaining bone health , especially in postmenopausal women .
19-1	3330-3334	Thus	_	_	_	_
19-2	3335-3336	,	_	_	_	_
19-3	3337-3340	the	abstract[180]	giv[180]	_	_
19-4	3341-3348	overall	abstract[180]	giv[180]	_	_
19-5	3349-3357	evidence	abstract[180]	giv[180]	_	_
19-6	3358-3364	points	_	_	_	_
19-7	3365-3371	toward	_	_	_	_
19-8	3372-3375	the	abstract[181]	giv[181]	_	_
19-9	3376-3380	role	abstract[181]	giv[181]	_	_
19-10	3381-3383	of	abstract[181]	giv[181]	_	_
19-11	3384-3387	the	abstract[181]|abstract[182]	giv[181]|giv[182]	coref	20-21[0_182]
19-12	3388-3390	MD	abstract[181]|abstract[182]	giv[181]|giv[182]	_	_
19-13	3391-3393	in	_	_	_	_
19-14	3394-3405	maintaining	_	_	_	_
19-15	3406-3410	bone	object|abstract[184]	giv|giv[184]	coref|coref	23-18|23-18
19-16	3411-3417	health	abstract[184]	giv[184]	_	_
19-17	3418-3419	,	_	_	_	_
19-18	3420-3430	especially	person[186]	giv[186]	_	_
19-19	3431-3433	in	person[186]	giv[186]	_	_
19-20	3434-3448	postmenopausal	event|person[186]	new|giv[186]	_	_
19-21	3449-3454	women	person[186]	giv[186]	_	_
19-22	3455-3456	.	_	_	_	_

#Text=Residual confounding factors in observational studies has become a major concern , with many international studies analyzing the relationship between diet and fracture risk .
20-1	3457-3465	Residual	abstract[187]	new[187]	coref	26-19[237_187]
20-2	3466-3477	confounding	abstract[187]	new[187]	_	_
20-3	3478-3485	factors	abstract[187]	new[187]	_	_
20-4	3486-3488	in	abstract[187]	new[187]	_	_
20-5	3489-3502	observational	abstract[187]|event[188]	new[187]|new[188]	coref	20-14[189_188]
20-6	3503-3510	studies	abstract[187]|event[188]	new[187]|new[188]	_	_
20-7	3511-3514	has	_	_	_	_
20-8	3515-3521	become	_	_	_	_
20-9	3522-3523	a	_	_	_	_
20-10	3524-3529	major	_	_	_	_
20-11	3530-3537	concern	_	_	_	_
20-12	3538-3539	,	_	_	_	_
20-13	3540-3544	with	_	_	_	_
20-14	3545-3549	many	event[189]	giv[189]	coref	21-15[199_189]
20-15	3550-3563	international	event[189]	giv[189]	_	_
20-16	3564-3571	studies	event[189]	giv[189]	_	_
20-17	3572-3581	analyzing	_	_	_	_
20-18	3582-3585	the	abstract[190]	new[190]	coref	26-8[231_190]
20-19	3586-3598	relationship	abstract[190]	new[190]	_	_
20-20	3599-3606	between	abstract[190]	new[190]	_	_
20-21	3607-3611	diet	abstract[190]|abstract	new[190]|giv	coref	22-18[207_0]
20-22	3612-3615	and	abstract[190]	new[190]	_	_
20-23	3616-3624	fracture	abstract[190]|abstract|abstract[193]	new[190]|giv|giv[193]	coref|coref	25-10|25-10
20-24	3625-3629	risk	abstract[190]|abstract[193]	new[190]|giv[193]	_	_
20-25	3630-3631	.	_	_	_	_

#Text=For instance , bias should be taken into account when considering meta-analysis results on prospective cohort studies beyond the Mediterranean region .
21-1	3632-3635	For	_	_	_	_
21-2	3636-3644	instance	_	_	_	_
21-3	3645-3646	,	_	_	_	_
21-4	3647-3651	bias	abstract	new	_	_
21-5	3652-3658	should	_	_	_	_
21-6	3659-3661	be	_	_	_	_
21-7	3662-3667	taken	_	_	_	_
21-8	3668-3672	into	_	_	_	_
21-9	3673-3680	account	abstract	new	coref	24-21
21-10	3681-3685	when	_	_	_	_
21-11	3686-3697	considering	_	_	_	_
21-12	3698-3711	meta-analysis	abstract|abstract[197]	new|new[197]	_	_
21-13	3712-3719	results	abstract[197]	new[197]	_	_
21-14	3720-3722	on	abstract[197]	new[197]	_	_
21-15	3723-3734	prospective	abstract[197]|event[199]	new[197]|giv[199]	coref	25-22[226_199]
21-16	3735-3741	cohort	abstract[197]|object|event[199]	new[197]|new|giv[199]	_	_
21-17	3742-3749	studies	abstract[197]|event[199]	new[197]|giv[199]	_	_
21-18	3750-3756	beyond	abstract[197]|event[199]	new[197]|giv[199]	_	_
21-19	3757-3760	the	abstract[197]|event[199]|place[200]	new[197]|giv[199]|new[200]	ana	22-1[0_200]
21-20	3761-3774	Mediterranean	abstract[197]|event[199]|place[200]	new[197]|giv[199]|new[200]	_	_
21-21	3775-3781	region	abstract[197]|event[199]|place[200]	new[197]|giv[199]|new[200]	_	_
21-22	3782-3783	.	_	_	_	_

#Text=This is due to the paucity of data and the lack of consensus on the definition of the MD .
22-1	3784-3788	This	place	giv	_	_
22-2	3789-3791	is	_	_	_	_
22-3	3792-3795	due	_	_	_	_
22-4	3796-3798	to	_	_	_	_
22-5	3799-3802	the	quantity[202]	new[202]	_	_
22-6	3803-3810	paucity	quantity[202]	new[202]	_	_
22-7	3811-3813	of	quantity[202]	new[202]	_	_
22-8	3814-3818	data	quantity[202]|abstract	new[202]|new	_	_
22-9	3819-3822	and	_	_	_	_
22-10	3823-3826	the	abstract[204]	new[204]	_	_
22-11	3827-3831	lack	abstract[204]	new[204]	_	_
22-12	3832-3834	of	abstract[204]	new[204]	_	_
22-13	3835-3844	consensus	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-14	3845-3847	on	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-15	3848-3851	the	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-16	3852-3862	definition	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-17	3863-3865	of	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-18	3866-3869	the	abstract[204]|abstract[205]|abstract[206]|abstract[207]	new[204]|new[205]|new[206]|giv[207]	coref	24-2[213_207]
22-19	3870-3872	MD	abstract[204]|abstract[205]|abstract[206]|abstract[207]	new[204]|new[205]|new[206]|giv[207]	_	_
22-20	3873-3874	.	_	_	_	_

#Text=Furthermore , physical activity has been demonstrated to be a robust indicator of a lower risk of bone fractures .
23-1	3875-3886	Furthermore	_	_	_	_
23-2	3887-3888	,	_	_	_	_
23-3	3889-3897	physical	abstract[208]	new[208]	coref	24-10[0_208]
23-4	3898-3906	activity	abstract[208]	new[208]	_	_
23-5	3907-3910	has	_	_	_	_
23-6	3911-3915	been	_	_	_	_
23-7	3916-3928	demonstrated	_	_	_	_
23-8	3929-3931	to	_	_	_	_
23-9	3932-3934	be	_	_	_	_
23-10	3935-3936	a	abstract[209]	new[209]	_	_
23-11	3937-3943	robust	abstract[209]	new[209]	_	_
23-12	3944-3953	indicator	abstract[209]	new[209]	_	_
23-13	3954-3956	of	abstract[209]	new[209]	_	_
23-14	3957-3958	a	abstract[209]|abstract[210]	new[209]|new[210]	coref	25-9[223_210]
23-15	3959-3964	lower	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-16	3965-3969	risk	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-17	3970-3972	of	abstract[209]|abstract[210]	new[209]|new[210]	_	_
23-18	3973-3977	bone	abstract[209]|abstract[210]|object|event[212]	new[209]|new[210]|giv|giv[212]	coref|coref	25-9|25-9
23-19	3978-3987	fractures	abstract[209]|abstract[210]|event[212]	new[209]|new[210]|giv[212]	_	_
23-20	3988-3989	.	_	_	_	_

#Text=Since a healthier diet is related to higher physical activity levels , the latter needs also to be taken into account .
24-1	3990-3995	Since	_	_	_	_
24-2	3996-3997	a	abstract[213]	giv[213]	coref	26-12[0_213]
24-3	3998-4007	healthier	abstract[213]	giv[213]	_	_
24-4	4008-4012	diet	abstract[213]	giv[213]	_	_
24-5	4013-4015	is	_	_	_	_
24-6	4016-4023	related	_	_	_	_
24-7	4024-4026	to	_	_	_	_
24-8	4027-4033	higher	abstract[215]	new[215]	_	_
24-9	4034-4042	physical	abstract[215]	new[215]	_	_
24-10	4043-4051	activity	abstract|abstract[215]	giv|new[215]	_	_
24-11	4052-4058	levels	abstract[215]	new[215]	_	_
24-12	4059-4060	,	_	_	_	_
24-13	4061-4064	the	_	_	_	_
24-14	4065-4071	latter	_	_	_	_
24-15	4072-4077	needs	_	_	_	_
24-16	4078-4082	also	_	_	_	_
24-17	4083-4085	to	_	_	_	_
24-18	4086-4088	be	_	_	_	_
24-19	4089-4094	taken	_	_	_	_
24-20	4095-4099	into	_	_	_	_
24-21	4100-4107	account	abstract	giv	_	_
24-22	4108-4109	.	_	_	_	_

#Text=The observed inverse association between dietary quality and bone fracture risk should be interpreted with caution because the case-control design of most studies ’ findings cannot indicate causality .
25-1	4110-4113	The	abstract[218]	new[218]	_	_
25-2	4114-4122	observed	abstract[218]	new[218]	_	_
25-3	4123-4130	inverse	place|abstract[218]	new|new[218]	_	_
25-4	4131-4142	association	abstract[218]	new[218]	_	_
25-5	4143-4150	between	abstract[218]	new[218]	_	_
25-6	4151-4158	dietary	abstract[218]|object|abstract[220]	new[218]|giv|new[220]	_	_
25-7	4159-4166	quality	abstract[218]|abstract[220]	new[218]|new[220]	_	_
25-8	4167-4170	and	abstract[218]	new[218]	_	_
25-9	4171-4175	bone	abstract[218]|object|abstract[223]	new[218]|giv|giv[223]	coref|coref|coref|coref	26-14|26-11[235_223]|26-14|26-11[235_223]
25-10	4176-4184	fracture	abstract[218]|abstract|abstract[223]	new[218]|giv|giv[223]	coref	26-15
25-11	4185-4189	risk	abstract[218]|abstract[223]	new[218]|giv[223]	_	_
25-12	4190-4196	should	_	_	_	_
25-13	4197-4199	be	_	_	_	_
25-14	4200-4211	interpreted	_	_	_	_
25-15	4212-4216	with	_	_	_	_
25-16	4217-4224	caution	abstract	new	_	_
25-17	4225-4232	because	_	_	_	_
25-18	4233-4236	the	abstract[225]	new[225]	_	_
25-19	4237-4249	case-control	abstract[225]	new[225]	_	_
25-20	4250-4256	design	abstract[225]	new[225]	_	_
25-21	4257-4259	of	abstract[225]	new[225]	_	_
25-22	4260-4264	most	abstract[225]|event[226]|abstract[227]	new[225]|giv[226]|new[227]	_	_
25-23	4265-4272	studies	abstract[225]|event[226]|abstract[227]	new[225]|giv[226]|new[227]	_	_
25-24	4273-4274	’	abstract[225]|event[226]|abstract[227]	new[225]|giv[226]|new[227]	_	_
25-25	4275-4283	findings	abstract[225]|abstract[227]	new[225]|new[227]	_	_
25-26	4284-4290	cannot	_	_	_	_
25-27	4291-4299	indicate	_	_	_	_
25-28	4300-4309	causality	abstract	new	_	_
25-29	4310-4311	.	_	_	_	_

#Text=There is a lack of research into the relationship between the MD and bone fracture risk that clarifies causation or confounding factors .
26-1	4312-4317	There	_	_	_	_
26-2	4318-4320	is	_	_	_	_
26-3	4321-4322	a	abstract[229]	new[229]	_	_
26-4	4323-4327	lack	abstract[229]	new[229]	_	_
26-5	4328-4330	of	abstract[229]	new[229]	_	_
26-6	4331-4339	research	abstract[229]|abstract	new[229]|new	_	_
26-7	4340-4344	into	_	_	_	_
26-8	4345-4348	the	abstract[231]	giv[231]	_	_
26-9	4349-4361	relationship	abstract[231]	giv[231]	_	_
26-10	4362-4369	between	abstract[231]	giv[231]	_	_
26-11	4370-4373	the	abstract[231]|abstract[235]	giv[231]|giv[235]	_	_
26-12	4374-4376	MD	abstract[231]|place|abstract[235]	giv[231]|giv|giv[235]	_	_
26-13	4377-4380	and	abstract[231]|abstract[235]	giv[231]|giv[235]	_	_
26-14	4381-4385	bone	abstract[231]|object|abstract[235]	giv[231]|giv|giv[235]	_	_
26-15	4386-4394	fracture	abstract[231]|abstract|abstract[235]	giv[231]|giv|giv[235]	_	_
26-16	4395-4399	risk	abstract[231]|abstract[235]	giv[231]|giv[235]	_	_
26-17	4400-4404	that	_	_	_	_
26-18	4405-4414	clarifies	_	_	_	_
26-19	4415-4424	causation	abstract|abstract[237]	new|giv[237]	_	_
26-20	4425-4427	or	abstract[237]	giv[237]	_	_
26-21	4428-4439	confounding	abstract[237]	giv[237]	_	_
26-22	4440-4447	factors	abstract[237]	giv[237]	_	_
26-23	4448-4449	.	_	_	_	_
